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Abstract Cisapride (Propulsid) is a gastrointestinal prokinetic 
agent commonly used to treat nocturnal heartburn as well as a 
variety of other gastrointestinal disorders. The use of cisapride 
has been associated with acquired long QT syndrome and 
ventricular arrhythmias such as torsades de pointes which 
produces sudden cardiac death. These cardiotoxic effects can 
be due to blockade of one or more types of K+ channel currents in 
the human heart. For this reason we compared the effects of 
cisapride on two cloned human cardiac K+ channels, Kvl.5 and 
the human ether-a-go-go-related gene (HERG) stably trans-
fected into mammalian cells. Using patch clamp electrophysiol-
ogy, we found that cisapride was a potent inhibitor of HERG 
displaying an IC50 value of 44.5 nmol/1 when tail currents at —40 
mV were measured following a 2 s test depolarization to +20 mV. 
When HERG currents were measured at the end of prolonged (20 
s) depolarizing steps to +20 mV, the apparent affinity of 
cisapride was increased and measured 6.70 nmol/1. The main 
effect of cisapride was to enhance the rate of HERG current 
decay thereby reducing current at the end of the voltage clamp 
pulse. Furthermore, the potency of cisapride for the HERG 
channel was similar to that observed for the class III 
antiarrhythmic agent dofetilide (IC50 = 15.3 nmol/1) and the 
nonsedating antihistamine terfenadine (IC50 = 56.0 nmol/1). In 
contrast to its effects on HERG, cisapride inhibited Kvl.5 
channel currents weakly displaying an IC50 value of 21.2 umol/l. 
It is concluded that cisapride displays specific, high affinity block 
of the human cardiac K+ channel HERG. It is likely that this 
interaction underlies the proarrhythmic effects of the drug 
observed under certain clinical settings. 
© 1997 Federation of European Biochemical Societies. 
1. Introduction 
Prolongation of cardiac repolarization is a dangerous side-
effect that is associated with some prescription medications. 
This proarrhythmic activity is characterized by a prolongation 
in the QT interval that can lead to the life-threatening ven-
tricular arrhythmia torsades de pointes [1]. One means by 
which drugs can prolong QT interval is through inhibition 
of one or more repolarizing K+ channel currents in the my-
ocardium. Advances in the field of molecular biology have led 
to the cloning of several distinct types of K+ channel proteins 
that contribute to repolarization in the human heart. For 
example, the rapidly activating delayed rectifier current, IKUT, 
which is prominent in human atria, is believed to be subserved 
by the cloned channel known as Kvl.5 [2]. The human ether-a-
go-go-related gene, HERG, expresses the delayed rectifier cur-
rent lier [3,4] which is found in both human ventricle and 
atria. HERG is especially relevant since mutations in this 
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gene lead to the type 2 hereditary form of long QT syndrome 
(LQT2) [3,4]. Furthermore, blockade of lKr is believed to 
cause acquired long QT syndrome associated with class III 
antiarrhythmic agents such as dofetilide [5]. 
Cisapride (Propulsid) is a gastrointestinal prokinetic agent 
which is widely prescribed for the treatment of gastroesophag-
eal reflux disease (GERD) [6]. In 1996 Propulsid ranked as the 
73rd most dispensed drug in the United States with over 
5.4 million prescriptions filled [7]. However, a number of re-
ports have now appeared linking cisapride use with QT pro-
longation and development of ventricular arrhythmias such as 
torsades de pointes [8-12]. This cardiotoxicity has been asso-
ciated with high doses of cisapride [10], or with the concom-
itant use of imidazole antifungals (e.g. ketoconazole) or mac-
rolide antibiotics (e.g. erythromycin) [11,12]. These drugs 
inhibit the cytochrome P-450 3A4 enzyme through which cis-
apride is metabolized thereby leading to higher blood levels of 
cisapride [11]. These reports have prompted the US Food and 
Drug Administration to issue a boxed warning on cisapride 
packaging for potential adverse cardiac events. This situation 
bears striking resemblance to that previously reported for the 
nonsedating antihistamine terfenadine (Seldane) whose use, 
under similar circumstances, may be associated with a prolon-
gation in cardiac repolarization [13]. We have previously 
shown that terfenadine can inhibit both Kvl.5 and HERG 
with its effects on HERG being approximately 10-fold more 
potent [14,15], making blockade of HERG the likely mecha-
nism to explain QT prolongation. The present report details 
the effects of cisapride on the cloned human cardiac channels 
Kvl.5 and HERG and establishes HERG as the likely target 
for QT prolongation. 
2. Materials and methods 
2.1. Molecular biology 
The cDNA encoding the human heart Kvl.5 potassium channel 
was transfected into the human embryonic kidney cell line HEK-
293 (American Type Culture Collection, Rockville, MD, #CRL-
1573) as described previously [2]. The entire Bam HI-digested 3.5 
kb HERG coding region from HERG-SP6 subcloned from a human 
neuroblastoma cell line (ATCC #HTB-11) was ligated with Bam HI-
digested pcDNA3 (Invitrogen), an eukaryotic expression vector. Cor-
rect orientation of the HERG gene just downstream from the CMV 
promoter was verified via dideoxy sequencing using the T7 oligo pri-
mer. The //£7?G-pcDNA3 plasmid was linearized within the ampicil-
lin resistance gene with Pvu-I and 3 (tg of the linearized HERG-
pcDNA was transfected into mouse L cells (ATCC #CCL-1) using 
50 ng of Lipofectin (GIBCO/BRL). The cells were replated in fresh 
medium containing 0.5 mg/ml Geneticin (GIBCO/BRL) 48 h after 
transfection and individual colonies were selected and expanded for 
continuous growth in G418. Total RNA was isolated from 24 differ-
ent clones using Stat-60 (Tel-Test 'B', Inc.). One ug of total RNA, 
along with HERG specific primers, were used in RT-PCR to assay for 
the presence of HERG mRNA. Five clones which contained the great-
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est amount of HERG message were then tested for HERG current. 
Cell line 13 (L-HERG 13) produced the largest HERG current and 
was used in all further experiments. 
2.2. Electrophysiology 
Cells used for electrophysiological recordings were seeded on glass 
coverslips 24-48 h before use. HERG currents were recorded using 
the whole-cell patch clamp configuration while Kvl.5 currents were 
recorded from cell-free inside-out membrane patches [16]. Electrodes 
(1^1 MQ resistance) were fashioned from TW150F glass capillary 
tubes (World Precision Instruments, New Haven, CT). For whole-
cell recordings electrodes were filled with the following solution 
(mmol/1): potassium aspartate, 120; KC1, 20; Na2ATP, 4.0; HEPES, 
5.0; MgCl2, 1.0; pH 7.2 with KOH. This served as the external sol-
ution for the inside-out patch experiments. The external solution for 
whole-cell recordings contained (mmol/1): NaCl, 130; KC1, 5.0; so-
dium acetate, 2.8; MgCl2, 1.0; HEPES, 10; glucose, 10; CaCl2, 1.0; 
pH 7.4 with NaOH. Currents were recorded at room temperature 
using an Axopatch 1-B amplifier (Axon Instruments, Burlingame, 
CA) and were conditioned by a 4-pole low-pass filter with a cutoff 
frequency of 500 or 200 Hz. Currents were stored and analyzed using 
a Compaq Deskpro computer and the pCLAMP suite of software 
(Axon Instruments). In most cases linear leakage and capacity cur-
rents were corrected on-line using the P/4 subtraction method. In 
some cases passive linear leak was recorded during 100 ms depolari-
zations between —75 and —50 mV and least-squares fit of the data 
was used for passive leak correction. The IC50 values for all com-
pounds were obtained by nonlinear least-squares fits of the data 
(GraphPAD Software, San Diego, CA). 
2.3. Chemicals 
Cisapride was obtained from Research Diagnostics, Inc. (Flanders, 
NJ). Dofetilide was obtained from Pfizer Central Research (Sandwich, 
Kent, England). Terfenadine was synthesized at Hoechst Marion 
Roussel, Inc. (Cincinnati, OH). All other compounds were obtained 
from Sigma Chemical Co. (St. Louis, MO). 
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3. Results 
Fig. 1 shows the effects of cisapride on HERG channel 
currents. In untransfected L cells no HERG-like K+ currents 
were detectable upon depolarization of the cells to +20 mV 
followed by a return potential of —40 mV (Fig. 1A). In cells 
stably transformed with the cDNA encoding HERG, slowly 
rising currents were apparent upon depolarization of the cell 
to +20 mV. The relationship between the current at the end of 
the pulse and membrane potential showed the characteristic 
bell-shaped relationship reflecting inward rectification at more 
positive potentials. Upon returning the cell to a potential of 
—40 mV, a large slowly deactivating tail current characteristic 
of HERG [3,14] was observed (Fig. IB). The tail current was 
potently blocked by cisapride resulting in an IC50 value of 
4.45 X 10"8 mol/1 (Fig. IB and C). Cisapride had no detectable 
effects on HERG tail current kinetics. When cells were re-
turned to a potential of —100 mV, inward HERG tail currents 
decayed with a time constant of 61.9 ±10.1 ms (n = 5). This 
value was unaltered in the presence of 1 X 10~7 mol/1 cisapride 
and measured 59.0 ± 5.0 ms (P>0.05, paired /-test). With this 
pulse protocol, the amplitude of the tail currents was reduced 
by 67 ± 3%. 
The waveform of the current at +20 mV in Fig. IB suggests 
that the blocking effects of cisapride were incomplete. To ex-
plore this phenomenon further, we examined the effects of 
cisapride on HERG currents induced by prolonged 20 s de-
polarizations to +20 mV. The extracellular K+ was increased 
to 20 mmol/1 to enhance current amplitude. Under these con-
ditions current in the absence of drug showed little decay (Fig. 
2A). Cisapride dramatically enhanced the rate of HERG cur-
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Fig. 1. Effects of cisapride on HERG. A: Untransfected L cells dis-
play no significant K+ channel currents. Whole-cell current was eli-
cited by a 2 s depolarizing pulse to +20 mV from a holding poten-
tial of —80 mV. The cell was then returned to —40 mV for 1.6 s. 
B; L cells stably transformed with the cDNA encoding HERG dis-
play slowly rising currents at +20 mV followed by large, slowly de-
activating outward tail currents at the return potential of —40 mV. 
These tail currents were potently blocked by cisapride as shown. C: 
Dose-response relationships for cisapride blockade of HERG. Peak 
tail currents at —40 mV following the test pulse to +20 mV were 
used to construct the HERG dose-response curve. The IC50 value 
and Hill slope measured 44.5 nmol/1 and —1.4, respectively. Error 
bars denote S.E.M. (n = 5-6). 
rent decay while having no apparent effect on the initial phase 
of current activation (Fig. 2A). Single exponential fit of the 
data yielded time constants for current decay ranging from 
11.65 ± 1.00 s at 10 nmol/1 to 0.85 ±0.08 s at 300 nmol/1 (Fig. 
2B). Finally, the IC50 value for cisapride block of HERG 
under these conditions measured 6.70 nmol/1 (Fig. 2C). 
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Fig. 2. Effects of cisapride on HERG during prolonged depolarization. A: HERG channel currents were elicited by a 20 s depolarization to 
+20 mV from a holding potential of —80 mV in the presence of 20 mM extracellular K+. A dose-dependent increase in the rate of current de-
cay in the presence of 10, 30 and 100 nmol/1 cisapride is shown. B: Drug-induced acceleration in current decay was fitted to a single exponen-
tial and plotted as a function of cisapride concentration. Error bars represent S.E.M. (« = 6-7). C: Dose-response relationship for cisapride 
blockade of HERG. Currents were sampled at the end of the 20 s depolarizing pulses to construct the dose-response relationship. The IC5o val-
ue and Hill slope measured 6.70 nmol/1 and —1.3, respectively. Bars represent S.E.M. (« = 4-7). 
Table 1 compares the ability of dofetilide, terfenadine and 
cisapride to inhibit HERG. Dofetilide, a class III antiarrhyth-
mic drug with high potency and specificity for IKr [5], inhib-
Table 1 
Effects of various drugs on HERG channel currents* 
Drug IC50 value ( ± standard error) 
Cisapride 
Dofetilide 
Terfenadine 
44.5 (±10.6) nmol/1 
15.3 (±2.5) nmol/1 
56.0 (±10.9) nmol/1 
aDose-response relationships were obtained as indicated in Fig. 1. 
ited HERG current with an IC50 value of 1.53 X 1(T8 mol/1. 
The nonsedating antihistamine terfenadine also potently 
blocked HERG current yielding an IC50 value of 5.60 X 10~8 
mol/1. These values are similar to those observed for the in-
hibition of HERG by cisapride under identical experimental 
conditions. 
Fig. 3 shows the effects of cisapride on another human 
cardiac K+ channel Kvl.5. As was the case for HERG, cis-
apride inhibited Kvl.5 channel current mainly by accelerating 
the rate of current decay during a depolarizing pulse (Fig. 
3A). However, the IC50 value for cisapride block of Kvl.5 
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Fig. 3. Effects of cisapride on Kvl.5. A: Kvl.5 current from an inside-out membrane patch was elicited by a 1 s test depolarization to +50 
mV from a holding potential of —80 mV. The effects of 10 and 30 umol/1 are shown. B: Dose-response relationship for cisapride blockade of 
Kvl.5. The last 50 ms of the depolarizing pulses to +50 mV were averaged to construct the dose-response curve. Concentrations of greater 
than 30 u.mol/1 could not be achieved due to solubility limitations of the drug. The IC50 value and Hill slope measured 21.2 |xmol/l and —0.84, 
respectively. Bars indicate S.E.M. (« = 4-7). 
was approximately 1000-fold higher than observed for inhib-
ition of HERG measuring 21.2 umol/1 (Fig. 3B). 
4. Discussion 
The present study demonstrates cisapride to be a potent 
antagonist of the HERG cardiac K+ channel. The inhibitory 
effects on HERG were most potent when the drug was al-
lowed to equilibrate with the channel during very prolonged 
depolarizations. Under these conditions cisapride enhanced 
the rate of current decay in a dose-dependent fashion with 
little effect on the initial time course of channel activation. 
These results suggest that cisapride blocks an activated state 
of HERG, possibly the open state. A similar mechanism may 
also explain cisapride's inhibition of Kvl.5, although much 
higher concentrations are necessary to produce inhibition of 
this cardiac K+ channel. Indeed, the IC5o value of 6.70 nmol/1 
obtained during the prolonged voltage steps shown in Fig. 2 
make cisapride one of the most potent antagonists of HERG 
yet described. The concentrations of cisapride needed to block 
HERG in the present study are likely to be encountered under 
certain clinical settings. Following therapeutic doses of cisap-
ride (10-20 mg), peak plasma concentrations of the drug can 
average 150-300 nmol/1 [6,17]. In the presence of ketoconazole 
or other agents which inhibit the cytochrome P450 3A4 en-
zyme system, levels of cisapride can be sharply higher [11,12]. 
Even when the extensive plasma protein binding of cisapride 
is considered (97-98%), concentrations of free drug can still 
reach levels similar to those reported here for blockade of 
HERG in vitro. Furthermore, blockade of HERG currents 
by cisapride was similar in potency to dofetilide and terfena-
dine, drugs which have been reported to produce acquired 
long QT syndrome in clinical settings [5,13]. 
To date, the mechanism whereby cisapride produces its car-
diotoxic effects has not been determined. Cisapride is a partial 
agonist at the serotonin 5-HT4 receptor and this mechanism 
has been proposed to underlie the drug's proarrhythmic ac-
tivity [9]. Alternatively, a procainamide-like effect on the at-
rioventricular node has also been postulated [8]. A study in 
rabbit Purkinje fibers has shown a class III antiarrhythmic 
effect of the drug which occurs at doses of 30 nmol/1 and 
higher [18]. Most recently cisapride has been shown to inhibit 
IKT in rabbit cardiomyocytes with an IC50 value of 9 nmol/1 
[19]. The gene product responsible for IKr in rabbit is un-
known but IKr is probably produced by a variant of the 
ether-a-go-go-related gene ERG [20]. The data presented 
here are the first to detail the interactions of cisapride with 
human cardiac K+ channels and strongly suggest that the 
molecular mechanism that underlies the proarrhythmic effects 
of cisapride is high affinity blockade of HERG. These findings 
also support to the hypothesis that blockade of HERG may 
play an important role in the development of many cases of 
32 
acquired long Q T syndrome. Future studies will likely un-
cover more drugs which share both proarrhythmic activity 
and clinically relevant blockade of H E R G . 
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